Does Kindred's Offer Make Sense for Gentiva Shareholders?

Gentiva Health  shareholders got some welcome news yesterday, as shares gained 62% in the wake of Kindred Health's announcement that it was taking its bid to acquire the company hostile.

So, good news on the price side, and the deal obviously makes sense from Kindred's perspective. But what about Gentiva's? Should shareholders support this deal for the opportunity to diversify away from government payers? Or should they support management, which claims that its "strategy as a stand-alone company will generate substantially more value to our shareholders"?

In this video, from Thursday's Market Checkup, the Motley Fool's health care focused show, health care analysts Michael Douglass and David Williamson consider the potential benefits to Gentiva and whether this is a good deal for shareholders.

Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

The article Does Kindred's Offer Make Sense for Gentiva Shareholders? originally appeared on

David WilliamsonMichael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story